Advanced Medical Solutions Group reported fiscal 2025 results that matched the trading update it issued in January, with the company highlighting robust expansion in its Surgical businesses alongside steady performance in Wound Care.
For the year, Advanced Medical Solutions recorded revenues of £228.9 million and adjusted EBITDA of £49.9 million, which equates to a 21.8% adjusted EBITDA margin. The company said these outcomes were in line with both its January trading statement and analyst consensus.
Surgical Care was the primary driver of top-line growth, posting 36% growth on a constant currency basis. Within the Surgical division, the ex-Peters segment increased by approximately 11% on a constant currency basis, supported by double-digit gains across most product categories. Divisional margins in Surgical finished at 24.4%, meeting the company's internal expectations.
Wound Care also expanded, with revenue up 9% on a constant currency basis. Management attributed the improvement to stronger performance in customer-branded items and bulk materials, together with growing traction for partners' products. The Wound Care division delivered a margin of 13.6%, in line with the prior guidance.
At a group level, earnings per share came in about 3% below FactSet consensus, a shortfall the company linked to higher interest expense. Advanced Medical Solutions said that operational synergies from its acquisitions are progressing as planned. The Peters acquisition completed in July 2024 and the Syntacoll acquisition completed in March 2024 are on track to deliver the anticipated benefits, with commercial synergies already contributing to revenue growth.
Looking ahead to fiscal 2026, the company expressed confidence in delivering revenue and EBITDA that are consistent with current market expectations. FactSet consensus figures cited by the company put expected revenue at £244.6 million and adjusted profit before tax at £40.6 million. Management expects continued strong growth in the Surgical franchise and more modest growth in Wound Care as long-term supply agreements come into effect.
Advanced Medical Solutions also outlined its capital and cash priorities, forecasting strong cash generation and a disciplined approach to capital allocation. The company said it will use cash to support deleveraging while continuing to invest in innovation and to optimize manufacturing. Management noted that it does not expect a material impact from the Middle East conflict.
Context and takeaways
- The group delivered results that were consistent with its own trading statement and with analyst expectations.
- Surgical Care is the principal growth engine, while Wound Care is growing more moderately as supply arrangements mature.
- Acquisition-related synergies are contributing to performance, though higher interest costs slightly reduced reported EPS versus consensus.